{"id":"NCT02255513","sponsor":"Ironshore Pharmaceuticals and Development, Inc","briefTitle":"A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD","officialTitle":"A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects With Attention-Deficit Hyperactivity Disorder.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2014-10","completion":"2014-10","firstPosted":"2014-10-02","resultsPosted":"2021-02-10","lastUpdate":"2021-06-30"},"enrollment":43,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"HLD200","otherNames":["methylphenidate hydrochloride (MPH)"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"HLD200","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will examine the efficacy and safety of HLD200 in patients age 6-12 years with ADHD using a classroom study design.","primaryOutcome":{"measure":"SKAMP","timeFrame":"8-hours from 8:00 am to 4:00 pm","effectByArm":[{"arm":"HLD200","deltaMin":11.8,"sd":1.63},{"arm":"Placebo","deltaMin":18.9,"sd":1.67}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["Headache","Abdominal pain upper","Fall","Bundle branch block right","Nausea"]}}